

3Q26 Results

RDsaúde

São Paulo, November 03, 2026. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 3rd quarter of 2026 (3Q26). The Company's parent company and consolidated financial statements for the periods ended September 30, 2026 and 2025 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year.

IFRS 16: Our financial statements are prepared in accordance with IFRS 16. To better reflect the economic reality of the business, the figures presented in this report consider the pre-IFRS 16 standard with a reconciliation available in a dedicated section of this document.

HIGHLIGHTS:

› Organic expansion maintains a strong pace

3.770 units in operation with 92 openings and 9 closures in the quarter;
333 LTM gross openings, reiterating the guidance of 330-350 gross openings in 2026;

› Sales growth remains strong and above inflation

Gross revenue of R$ 13.2 billion, +16.0% growth and a R$ 1.8 billion increment;
MSSS growth of +8.4%, a real growth +5.6 pp above the annual CMED adjustment;

› Market share gains in every region

19.1% national share, a +1.1 pp increase with gains in every region;

› Digital sales combine scale and omnichannel leadership

Gross revenue of R$ 3.8 billion, +27.2% growth and retail penetration of 29.4%;

› Growth with resilient margins

Adjusted EBITDA of R$ 1.0 billion, +14.7% & margin of 7.8% (-0.1 pp);
Adjusted net income of R$ 439 MM, +9.2% (including 4Bio) & margin of 3.3% (-0.2 pp);
Excluding 4Bio impacts, net income growth of +20.1% & margin expansion of +0.1 pp;

› Low leverage with cash generation

R$ 160 MM positive free cash flow and R$ 57 MM total cash generation;
0.8x ND/EBITDA, a 0.3x reduction.

RADL3
R$ 15.22/share
Closing Oct 30, 2026

MARKET CAP
R$ 26.7 billion

NUMBER OF SHARES
1,752,367,344
All ordinary

IR TEAM:
Flávio Correia
André Stolfi
Victor Torres
Felipe Correa


ir.rdsaude.com.br
ri@rdsaude.com.br

New consolidated summary (ex-4Bio)

In R$ thousands	3Q25	4Q25	1Q26	2Q26	3Q26
# of pharmacies	**3,453**	**3,547**	**3,614**	**3,687**	**3,770**
Organic openings	88	97	68	76	92
Closures	(6)	(3)	(1)	(3)	(9)
Headcount (EoP)	69,860	73,388	75,190	75,594	77,428
Pharmacist count (EoP)	13,981	14,377	14,965	15,199	15,478
# of tickets (thousands)	111,543	114,731	111,849	119,305	119,277
# of active customers (MM)	51.0	51.7	52.3	52.8	53.3
Gross revenue	**11,347,942**	**12,186,767**	**11,979,521**	**12,777,743**	**13,163,282**
Growth (YoY)	+15.5%	+22.3%	+20.4%	+18.3%	+16.0%
Gross profit	3,257,291	3,508,601	3,392,636	3,696,071	3,795,614
% of gross revenue	28.7%	28.8%	28.3%	28.9%	28.8%
Adjusted EBITDA	**892,592**	**924,318**	**820,786**	**1,017,348**	**1,023,739**
% of gross revenue	7.9%	7.6%	6.9%	8.0%	7.8%
Adj. net income (w/ 4Bio)	**401,986**	**361,654**	**299,752**	**432,729**	**439,124**
% of gross revenue	3.5%	3.0%	2.5%	3.4%	3.3%
Free cash flow	**615,609**	**(466,520)**	**284,869**	**549,989**	**160,161**


STORE DEVELOPMENT

Pharmacy count



	3Q25	4Q25	1Q26	2Q26	3Q26	LTM
Gross openings	**+88**	**+97**	**+68**	**+76**	**+92**	**+333**
Closures	-6	-3	-1	-3	-9	-16
- Maturing	-	*-1*	-	-	*-2*	*-3*
- Mature	*-6*	*-2*	*-1*	*-3*	*-7*	*-13*
Net openings	**+82**	**+94**	**+67**	**+73**	**+83**	**+317**

Pharmacy portfolio by age




We ended 3Q26 with a total of 3,770 pharmacies in operation, opening 92 new units in the quarter and 333 LTM. We reiterate our guidance of 330-350 gross openings for 2026.


We closed 9 units in 3Q26 totaling 16 LTM, with only 3 still in the maturation process. This equates to less than 1% of the LTM openings, highlighting the precision of our expansion process. The remaining 13 LTM closures were of mature units with an average of 11 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC.

At the end of 3Q26, a total of 25.2% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.


Number of cities with pharmacies



Pharmacies by region



Pharmacies by format




Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 697 cities in every state, +44 vs. the prior year, a unique capillarity in Brazilian retail under direct management.

We maintained a consistent expansion pace in São Paulo, our largest market, sustaining 35% of the LTM expansion plan. Even with our broad presence in the state, we continue to identify meaningful opportunities and see solid performance from newly opened stores, reinforcing the potential to grow profitably across the country.


Lastly, the IRR of new pharmacies continues sustaining record levels, reflecting greater expansion assertiveness supported by the recent efficiency gains in operations, the omnichannel performance, the emerging GLP-1 market, among other factors.

Geographic presence



Retail Market Share

Quarterly share, customer prices, sell-out + sell-in



Source: IQVIA. Southeast excludes SP.

Our 3.8 thousand pharmacies are present in every state in the country and supported directly by an integrated network of 16 distribution centers. This logistics grid allows us to serve more than 80% of our locations daily with lead times of up to 24 hours. As a result, we sustain high service levels, optimize working capital, and strengthen operational efficiency, establishing a significant competitive advantage.

Our national market share reached 19.1% in the quarter, a solid gain of +1.1 pp vs. the prior year. In addition, we recorded relevant gains across all regions, underscoring our competitive strength in diverse contexts and markets. Market shares reached 33.0% in São Paulo (+1.1 pp), 14.3% in the Southeast (+1.1 pp), 24.8% in the Midwest (+1.9 pp), 11.5% in the South (+0.5 pp), 14.2% in the Northeast (+1.3 pp), and 12.1% in the North (+1.0 pp).


The +1.1 pp gain in national market share includes the sequential stabilization of GLP-1 products near a 12% share of retail sales. Excluding GLP-1 items, our total market share gain continued robust, a little below +1 pp, with gains across every region.

DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT

We continued to advance our digital strategy, further strengthening our relationship with the customer. In the last 12 months, we recorded over 1 billion visits across our digital channels, an impactful audience that enhances our role in promoting health. In addition, digitalization increases spending per customer, with digitally engaged loyal customers spending 30% more than the average loyal customer.


Digital sales and penetration

R$ millions, % of retail gross revenue



Digital channel mix

% of quarterly digital sales




80 NPS
App rating

R$ 14.9 B
LTM digital sales

Delivery mix

% of quarterly digital sales



83 NPS
Delivery rating

>1 billion visits
Via apps and website LTM

We recorded R$ 3.8 billion in digital channel gross revenue in 3Q26, a growth of +27% vs. the prior year. The share of these channels was 29.4% of retail sales, an increase of +2.7 pp.

The share of digital channels within sales recorded a sequential decrease of -1.6 pp, entirely driven by the new pricing policy that now offers the same GLP-1 discounts in-store, previously exclusive to digital purchases. As a result, the participation of physical channels in this product category increased from 25% in 2Q26 to 40% in October 2026, once again showcasing the importance of the physical pharmacy presence in the customer's health journey. Tthe remaining product categories continued gaining digital penetration.


Among our digital channels, we highlight the intense use of our apps, in which our customers enjoy the best mobile experience specialized in omnichannel health and wellness journeys. Digital sales through apps increased +30% vs. the prior year, with a dominant 83% share of digital sales in the quarter.


This evolution in customer digitalization, leveraging our modern and proprietary channels, reflects the ongoing improvement of our mobile experience and a more complete, fully omnichannel health journey. It enhances the capillarity of our store network, which has 95% of the A-Class population within a 1.5 km radius and enables 96% of digital orders to be delivered or picked up in less than 60 minutes with high economic efficiency.

The customer omnichannel experience is strengthened by Stix, our loyalty ecosystem that joins over 9,000 points of sale from the brands Drogasil, Raia, Pão de Açúcar, Extra, Shell and Petlove, in addition to the financial partners Itaú and Livelo. In July 2026, RD Saúde acquired from GPA the remaining 67% of the capital of Stix, taking leadership of the coalition that benefitted 15.6 million active customers, a 26% increase vs. the prior year, of which 6.8 million interacted with 2 or more of the partners.

Lastly, we continued to strengthen the role of our pharmacies in the customer's integral health journey, positioning our locations as health hubs within the communities we serve and expanding engagement through pharmaceutical services. We now have 3.2 thousand units with *Mais Saúde* hubs and their expanded services portfolio, in addition to 462 units enabled for vaccination. In 3Q26, more than 2.2 million pharmaceutical services were performed, including CATs (clinical analysis tests), vaccinations, and other services, recording an NPS superior to the pharmacy average of 91.


GROSS REVENUES






We ended 3Q26 with R$ 13,163 million in gross revenue, a 16.0% growth vs. the prior year and a relevant increment of R$ 1.8 billion, in a quarter with a negative calendar effect of 0.3 pp. This pace of growth is in-line with expectations given the stabilization since 4Q25 of GLP-1 items within the products mix. Furthermore, the incorporation of Stix in 3Q26 contributed +0.4 pp to the quarter's consolidated growth.

We sustained a robust growth across all categories. Branded Rx grew +19.8% in the quarter, still growing at double-digit rates when excluding GLP-1 products. We highlight that the recent launching of new GLP-1 semaglutide products improves customer accessibility, with the additional unit volume offsetting the relevant reduction in average prices, still sustaining revenue. We note that we still observe limited supply from the industry for these new brands. Meanwhile, the other categories displayed positive performance: Generics grew +11.7%, HPC +13.4%,.and OTC +10.8%, despite a milder winter, above-average rain in the South and Southeast and weaker demand for seasonal items.



Finally, we recorded average same-store sales growth of +10.1% in 3Q26. Among mature stores, which completed the full 3-year ramp-up, we posted an average growth of +8.4%, a pace 5.6 pp above the 2.8% CMED price adjustment authorized in 2026 and 3.8 pp above the LTM CPI. We highlight that, aligned with the market share gains, mature-store performance was strong in all regions, underscoring the elevated competitiveness of our brands within the different market environments.

GROSS PROFIT




Gross profit totaled R$ 3,795.6 million in 3Q26, equivalent to a gross margin of 28.8% with a 0.1 pp expansion vs. the prior year. The incorporation of Stix in 3Q26 contributed with .2 pp.

We recorded a 0.2 pp pressure from the NPV adjustments, reflecting the lower Selic interest rate, in addition to pressures from the greater mix of GLP-1 products and of digital channels. These pressures were offset by lower inventory losses and from commercial gains.


SELLING EXPENSES

Selling expenses totaled R$ 2,429.0 million in 3Q26, equivalent to 18.5% of gross revenue, a 0.3 pp pressure vs. the prior year. There we no material effects from the incorporation of Stix.

This quarter still includes the 0.5 pp pressure stemming from the 4Q25 investments into our Employee Value Proposition (EVP), in addition to lesser pressures from expenses with security services and last mile deliveries. These were partly offset by dilutions in rentals and payment processing fees, in addition to an important operating leverage derived from the strong mature-store sales growth above inflation.



GENERAL & ADMINISTRATIVE EXPENSES




RD Saúde's corporate structure continued delivering operating leverage. The incorporation of Stix in 3Q26 led to general and administrative expenses totaling R$ 342.9 million, corresponding to 2.6% of gross revenue, stable vs. the prior year. Without Stix, G&A expenses would represent 2.4% of gross revenue, a 0.2 pp dilution.

We highlight that the sequential increase in G&A expenses is expected given the provision for the yearly salary adjustment in the state of São Paulo, where our headquarters are located.


EBITDA


We recorded an adjusted EBITDA of R$ 1,023.7 million in 3Q26, a 14.7% expansion vs. the prior year. The EBITDA margin was of 7.8% of gross revenue, a 0.1 pp contraction, which in this quarter still includes the effects of the investments into our employee value proposition (EVP).


The incorporation of Stix in 3Q26 contributed with 0.1 pp to the quarter's EBITDA margin.



DEPRECIATION, NET FINANCIAL EXPENSES AND EBT








Adjusted depreciation expenses totaled R$ 300.0 million in 3Q26, equivalent to 2.3% of gross revenue, stable vs. the prior year.


Adjusted net financial expenses totaled R$ 174.9 million in 3Q26, representing 1.3% of gross revenue, a strong dilution of 0.6 pp vs. the prior year. This dilution includes 0.4 pp stemming from the impacts of a lower average Selic rate upon financial liabilities, resulting in R$ 119.9 million in net financial expenses (0.9% of gross revenue). Additionally, we recorded a financial revenue of R$ 22.7 million from the sale of 4Bio.

We also recorded a 0.2 pp dilution from the non-cash NPV adjustment, equivalent to R$ 54.9 million (0.4% of gross revenue).

Lastly, we recorded an increase of 31.0% in our adjusted EBT vs. the prior year, totaling R$ 547.6 million in 3Q26. This was equivalent to 4.2% of gross revenue, a 0.5 pp expansion.

INCOME TAXES AND NET INCOME





We provisioned a total of R$ 108.5 million in adjusted income tax in 3Q26, 0.8% of gross revenue, an increase of 0.2 pp vs. the prior year. The effective tax rate was 19.8% of EBT, an increase of 2.8 pp driven by the lower proportion of interest on equity provisioned in the quarter. The YTD recurring effective tax rate was of 19.4%.

Adjusted consolidated net income was of R$ 439.1 million in 3Q26, with a net margin of 3.3% of gross revenue. There was no material effect from the incorporation of Stix.

When excluding the effects of 4Bio, both its operational profit in 3Q25 (R$ 55.2 million, which included non-recurring tax gains) and the financial revenue in 3Q26 stemming from its sale (R$ 22.7 million), we recorded a net margin of 3.2% in this quarter with a 0.1 pp expansion and an earnings growth of 20.1%. These earnings and margin improvements underscore the resilient aspect of the business, which boasts a solid track record in navigating different economic and political backdrops. We also highlight that these earnings improvements will continue to be complemented by the financial revenue stemming from the sale of 4Bio.

EBITDA & NET INCOME RECONCILIATION AND NON-RECURRING RESULTS

Adjusted EBITDA & Net Income Reconciliation (R$ millions)	**3Q25**	**3Q26**
Net income	**476.1**	**426.9**
Results of discontinued operations (4Bio)	(92.1)	0.0
Income tax	90.2	102.2
Equity equivalence	(1.0)	1.3
Financial result	210.9	174.9
EBIT (ex-4Bio)	**684.0**	**705.2**
Depreciation and amortization	264.8	300.0
EBITDA (ex-4Bio)	**948.8**	**1,005.2**
Asset write-offs	1.3	1.5
Social investments and donations	1.6	0.6
Tax effects from previous years	(15.6)	13.0
Other non-recurring/non-operating effects	(43.6)	3.4
Adjusted EBITDA (ex-4Bio)	**892.6**	**1,023.7**
Net income	**476.1**	**426.9**
Net non-rec. effects of discont. operations (4Bio)	(37.0)	-
Non-recurring EBITDA effects	(56.2)	18.6
Non-rec. effects of cont. op. on income taxes (34%)	19.1	(6.3)
Adjusted net income	**402.0**	**439.1**


Within our EBITDA, we recorded R$ 18.6 million in net non-recurring expenses in the 3Q26. This includes expenses of R$ 1.5 million in asset write-offs, R$ 0.6 million in social investments & donations, R$ 13.0 million related to tax effects of previous years and R$ 3.4 million in other non-recurring effects. In net income, we recorded a reduction of R$ 6.3 million in income taxes from the non-recurring effects.

CASH CYCLE

We recorded a cash cycle improvement of 2.4 days vs. the prior year, totaling 54.2 days in 3Q26. This is already adjusted for discounted receivables, forward payments to suppliers, and also includes the positive effects derived from the end of the ICMS-ST tax regime in the state of São Paulo.

We recorded increases of 1.4 days in inventories, due to the lower sales of seasonal items, and of 0.6 days in receivables, more than offset by an increase of 4.4 days in suppliers.

Cash cycle*



* Adjusted for discounted receivables & advanced payments to suppliers.

CASH FLOW

Cash Generation and Net Debt Reconciliation (R$ millions)	3Q25 Ex-4Bio	3Q26
Adjusted EBIT	**627.8**	**723.7**
NPV adjustment	(71.1)	(59.8)
Non-recurring effects	56.2	(18.6)
Income tax (34%)	(208.4)	(219.4)
Depreciation	255.2	298.5
Impairment provision (4Bio)	-	0.2
Others	125.2	46.5
Resources from operations	**784.9**	**771.1**
Cash cycle*	123.5	(394.8)
Other assets (liabilities)**	74.4	202.1
Operating cash flow	**982.7**	**578.5**
Investments	(367.1)	(418.3)
Free cash flow	**615.6**	**160.2**
Investment activities in investees	(31.5)	(31.7)
Interest on equity and dividends	(0.1)	(0.1)
Income tax paid over interest on equity	(18.4)	(27.6)
Net financial expenses***	(145.1)	(119.9)
Tax benefit (fin. exp., IoE, dividends)	97.2	95.1
Total cash flow (ex-4Bio)	**517.7**	**75.9**
Effects from discontinued operations (4Bio)	40.6	(19.0)
Total (including 4Bio effects)	**558.3**	**56.8**

*Includes adjustments to discounted receivables. **Incl. NPV. ***Excl. NPV.

We generated R$ 56.8 million in 3Q26. This includes a cash generation in resources from operations of R$ 771.1 million (5.9% of gross revenue), and an operating cash flow of R$ 578.5 million.

We invested R$ 192.7 million in working capital and R$ 418.3 million in CAPEX, comprising of R$ 175.4 million for new pharmacy openings, R$ 90.5 million for maintenance and renovation of existing pharmacies, R$ 86.8 million for technology, R$ 61.9 million for logistics and R$ 3.8 million for other projects.

Net financial expenses totaled R$ 119.9 million in 3Q26, partially offset by a tax deduction of R$ 95.1 million related to financial expenses and interest on equity (IoE). Finally, we announced R$ 159.8 million in IoE in 3Q26.

INDEBTEDNESS

Net debt ex-4Bio (R$ millions)	3Q25	4Q25	1Q26	2Q26	3Q26
Short-term debt	522.5	508.1	425.5	365.3	417.3
Long-term debt	2,760.1	3,359.6	3,236.1	3,087.4	3,088.6
Total gross debt	**3,282.6**	**3,867.8**	**3,661.5**	**3,452.6**	**3,505.9**
(-) Cash and equivalents	339.6	358.6	441.8	536.5	504.0
Net debt	**2,943.0**	**3,509.1**	**3,219.7**	**2,916.1**	**3,001.9**
Discounted receivables	514.7	800.3	953.6	808.9	621.1
Advances to suppliers	(3.7)	-	-	(25.7)	-
Sale of 4Bio - Pending receivables	-	-	-	(716.4)	(697.4)
Investment put/call options (estimated)	22.8	15.5	15.9	16.6	17.1
Adjusted net debt	**3,476.7**	**4,324.9**	**4,189.2**	**2,999.6**	**2,942.7**
LTM adjusted EBITDA	3,056.3	3,303.1	3,500.7	3,655.0	3,786.2
Adjusted net debt/LTM EBITDA	**1.1x**	**1.3x**	**1.2x**	**0.8x**	**0.8x**

We ended the 3Q26 with an adjusted net debt of R$ 2,942.7 million, corresponding to a financial leverage ratio of 0.8x the adjusted EBITDA for the last 12 months, a 0.3x leverage reduction vs. the prior year. This reduction is comprised of 0.1x from the regular cash generation of operations and 0.2x from the sale of 4Bio.


Our adjusted net debt considers a balance of R$ 621.1 million in discounted receivables, R$ 697.4 million in pending receivables related to the sale of 4Bio and R$ 17.1 million in obligations related to put/call options for remaining equity interests in investee companies.

Gross debt totaled R$ 3,505.9 million, fully comprised by the issuance of Debentures and Real Estate Receivables Certificates (CRIs), all with a reaffirmed AAA.br rating from Moody's. Of total indebtedness, 88% is long-term and 12% is short-term. We ended the quarter with a total cash and equivalents position of R$ 504.0 million.

We highlight that, despite already recording a low leverage of 0.8x, we expect additional cash generation over time from the recovery of ICMS-ST taxes in the state of São Paulo.

TOTAL SHAREHOLDER RETURNS

Stock price appreciation (Index 100 = June 2007)



Our share price increased by 10.0% in 3Q26, while the IBOVESPA index increased by 7.0%. During the period, the average daily trading volume (ADTV) was of R$ 192.2 million.

Since the IPO of Drogasil in June 2007, we achieved a cumulative share appreciation of 2,220%, compared to only 238% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 18.5%.

Considering the IPO of Raia in December 2010, the cumulative return amounted to 566%, compared to 174% for the IBOVESPA. Including shareholder distributions, this equates to an average annual return of 13.7%.

IFRS-16

Since 2019, the financial statements have been prepared in accordance with IFRS 16. However, for historical comparability purposes, the figures presented in this report exclude the effects of this standard, as we believe the previous accounting approach better reflects the economic reality of our business. On RD Saúde's Investor Relations website (ir.rdsaude.com.br), the financial statements can be found in the 'Results Spreadsheets' section.

	3Q26		Change
Income Statement *(R$ millions)*	**Pre IFRS 16**	**IFRS 16**	**Δ 3Q26**
Gross Revenue	**13,163.3**	**13,163.3**	**0.0**
Gross Profit	**3,795.6**	**3,797.3**	**1.7**
Gross Margin	28.8%	28.8%	0.0 pp
Selling Expenses	(2,429.0)	(2,061.2)	367.7
G&A	(342.9)	(342.0)	0.9
Total Expenses	**(2,771.9)**	**(2,403.2)**	**368.6**
as % of Gross Revenue	21.1%	18.3%	(2.8 pp)
Adjusted EBITDA	**1,023.7**	**1,394.1**	**370.3**
as % of Gross Revenue	7.8%	10.6%	2.8 pp
Non-Recurring Expenses / Revenues	(18.6)	(16.5)	2.0
Depreciation and Amortization	(300.0)	(561.5)	(261.5)
Financial Results	(174.9)	(314.0)	(139.1)
Income Tax	(102.2)	(92.6)	9.6
Net income ex-4Bio	**426.9**	**408.3**	**(18.6)**
as % of Gross Revenue	3.2%	3.1%	(0.1 pp)
Net Income	**426.9**	**408.2**	**(18.6)**
as % of Gross Revenue	3.2%	3.1%	(0.1 pp)

	3Q26		Change
Balance Sheet *(R$ millions)*	**Pre IFRS 16**	**IFRS 16**	**Δ 3Q26**
Assets	**20,766.0**	**25,624.7**	**4,858.6**
Current Assets	**14,636.7**	**14,636.7**	**(0.0)**
Non-Current Assets	**6,129.3**	**10,988.0**	**4,858.6**
Income Tax and Social Charges deferred	53.3	291.0	237.7
Other Credits	560.8	560.4	(0.5)
Investments	0.2	0.0	(0.2)
Right of use	0.0	4,621.5	4,621.5
Liabilities and Shareholder's Equity	**20,766.0**	**25,624.7**	**4,858.6**
Current Liabilities	**9,445.7**	**10,479.1**	**1,033.3**
Financial Leases	0.0	1,039.8	1,039.8
Other Accounts Payable	610.2	603.8	(6.4)
Non-Current Liabilities	**3,307.1**	**7,594.1**	**4,287.0**
Financial Leases	0.0	4,287.0	4,287.0
Shareholder's Equity	**8,013.2**	**7,551.5**	**(461.7)**
Income Reserves	2,489.1	2,075.7	(413.4)
Accrued Income	528.2	479.8	(48.3)
Equity Adjustments	63.0	63.0	(0.1)

Cash Flow *(R$ millions)*	3Q26 Pre IFRS 16	3Q26 IFRS 16	Change Δ 3Q26
Adjusted EBIT	**723.7**	**832.6**	**108.9**
Non-Recurring Effects	(18.6)	(16.5)	2.0
Income Tax (34%)	(219.4)	(257.1)	(37.7)
Depreciation	298.5	561.5	263.0
Rental Expenses	0.0	(370.7)	(370.7)
Impairment provision (4Bio)	0.2	0.2	0.0
Others	46.5	81.2	34.7
Resources from Operations	**771.1**	**771.4**	**0.2**
Operating Cash Flow	**578.5**	**578.5**	**0.0**
Investments	**(418.3)**	**(418.3)**	**0.0**
Free Cash Flow	**160.2**	**160.2**	**0.0**
Total cash flow (ex-4Bio)	**75.9**	**75.9**	**0.0**
Total cash flow (with 4Bio)	**56.8**	**56.8**	**0.0**

GLOSSARY

OTC – Over the Counter

Digital sales – Sales through digital channels, such as apps, e-commerce, phone, digital partners, among others

DC – Distribution Center

CMED – Inter-ministerial government body responsible for the economic regulation of Brazil's medicine market

EBITDA – Earnings Before Interest, Taxes, Depreciation and Amortization

MSSS/SSS – Mature Same-Store Sales/Same-Store Sales

LTM – Last Twelve Months

NPV – Net Present Value

EVP – Employee Value Proposition

Adjusted EBITDA – EBITDA excluding non-recurring results

RESULTS CONFERENCE CALL

November 04, 2026 - 10:00 AM (UTC-3), with simultaneous translation to English.

Access link
https://www.resultadosrdsaude.com.br/

For more information, please contact our Investor Relations department: ri@rdsaude.com.br

Consolidated adj. income statement (R$ thousands)	3Q25 Resubmitted	3Q26
Gross revenue	**11,347,942**	**13,163,282**
Taxes, deductions and returns	(767,440)	(1,754,278)
Net revenue	**10,580,502**	**11,409,004**
Cost of goods sold	(7,323,211)	(7,613,390)
Gross profit	**3,257,291**	**3,795,614**
% of gross revenue	28.7%	28.8%
Selling expenses	(2,064,781)	(2,428,957)
General and administrative expenses	(299,919)	(342,917)
Operational expenses	**(2,364,700)**	**(2,771,875)**
% of gross revenue	(20.8%)	(21.1%)
Adjusted EBITDA	**892,592**	**1,023,739**
% of gross revenue	7.9%	7.8%
Depreciation and amortization	(264,817)	(300,007)
Adjusted EBIT	**627,775**	**723,732**
Financial expenses	(340,850)	(337,366)
Financial revenue	129,924	162,494
Adjusted financial results	**(210,926)**	**(174,873)**
Equity equivalence	1,034	(1,253)
Adjusted EBT	**417,883**	**547,606**
Income tax and social charges	(71,071)	(108,468)
Adjusted net income ex-4Bio	**346,812**	**439,139**
% of gross revenue	3.1%	3.3%
Discontinued operations (4Bio)	55,174	(15)
Adjusted net income	**401,986**	**439,124**
% of gross revenue	3.5%	3.3%

Consolidated income statement (R$ thousands)	3Q25 Resubmitted	3Q26
Gross revenue	**11,347,942**	**13,163,282**
Taxes, deductions and returns	(767,440)	(1,754,278)
Net revenue	**10,580,502**	**11,409,004**
Cost of goods sold	(7,323,211)	(7,613,390)
Gross profit	**3,257,291**	**3,795,614**
Selling expenses	(2,064,781)	(2,428,957)
General and administrative expenses	(299,919)	(342,917)
Other operational expenses, net	56,244	(18,563)
Operational expenses	**(2,308,456)**	**(2,790,438)**
EBITDA	**948,835**	**1,005,176**
Depreciation and amortization	(264,817)	(300,007)
EBIT	**684,018**	**705,169**
Financial expenses	(340,850)	(337,366)
Financial revenue	129,924	162,494
Financial results	**(210,926)**	**(174,873)**
Equity equivalence	1,034	(1,253)
EBT	**474,126**	**529,043**
Income tax and social charges	(90,194)	(102,156)
Net income ex-4Bio	**383,933**	**426,887**
Results of discontinued operations (4Bio)	92,145	(15)
Net income	**476,078**	**426,872**

Assets (R$ thousands)	3Q25	3Q26
Cash and cash equivalents	339,615	503,986
Financial investments	102,050	123,210
Accounts receivable	2,848,274	3,372,755
Inventories	8,125,437	8,568,312
Taxes receivable	466,246	908,247
Anticipated expenses	115,993	170,426
Judicial deposits	6,825	3,027
Assets of investment for sale (4Bio)	1,504,998	-
Other accounts receivable	608,926	986,743
Current assets	14,118,364	14,636,706
Deposit in court	58,853	65,317
Taxes receivable	233,345	270,646
Income tax and social charges deferred	46,164	53,301
Other credits	9,951	560,844
Investments	16,660	186
Property, plant and equipment	2,822,576	3,102,481
Intangible	2,064,727	2,076,551
Non-current assets	5,252,276	6,129,326
TOTAL ASSETS	**19,370,640**	**20,766,031**

Liabilities and shareholder equity (R$ thousands)	3Q25	3Q26
Suppliers	5,739,195	6,340,844
Loans and financing	522,497	417,271
Salaries and social charges payable	895,260	1,044,588
Taxes payable	453,140	570,626
Dividends and interest on equity	338,196	437,411
Provision for lawsuits	48,336	24,810
Liabilities of investment for sale (4Bio)	551,325	-
Other accounts payable	442,815	610,196
Current liabilities	8,990,764	9,445,746
Loans and financing	2,760,116	3,088,611
Provision for lawsuits	143,283	167,493
Income tax and social charges deferred	2,356	(49)
Other accounts payable	64,948	51,024
Non-current liabilities	2,970,703	3,307,078
Common stock	4,000,000	4,750,000
Capital reserves	125,346	172,087
Revaluation reserve	10,991	10,862
Income reserves	2,529,320	2,489,084
Accrued income	666,109	528,151
Equity adjustments	62,969	63,023
Non controller interest	14,437	-
Shareholder equity	7,409,172	8,013,207
TOTAL LIABILITIES & SHAREHOLDER EQUITY	**19,370,640**	**20,766,031**

Cash Flow (R$ thousands)	3Q25	3Q26
Earnings before Income Tax and Social Charges	**566,263**	**529,043**
Adjustments		
Depreciation and Amortization	256,356	298,522
Compensation plan with restricted shares, net	(5,761)	12,265
Interest over additional stock option	8,325	569
PP&E and Intangible Assets residual value	7,717	7,556
Provisioned Lawsuits	44,727	28,375
Provisioned Inventory Loss	8,939	(1,777)
Provision for Doubtful Accounts	5,500	3,918
Provisioned Store Closures	(330)	(3,810)
Interest Expenses	155,720	124,905
Debt Issuance Costs Amortization	2,326	1,891
Equity Equivalence Result	(1,026)	1,235
Provision for realization of recoverable investment	-	206
	1,048,756	**1,002,898**
Assets and Liabilities variation		
Clients and Other Accounts Receivable	(387,034)	(280,926)
Inventories	(183,482)	(232,639)
Other Short Term Assets	18,108	(120,328)
Suppliers	465,443	(43,370)
Salaries and Social Charges	118,243	119,033
Taxes Payable	6,674	161,244
Other Liabilities	(107,088)	(34,661)
Rents Payable	5,004	(15,613)
Cash from Operations	**984,624**	**555,638**
Interest Paid	(122,531)	(73,499)
Income Tax and Social Charges Paid	(81,744)	(43,401)
Paid lawsuits	(29,694)	(23,370)
Discontinued operational activities (4Bio)	-	2,252
Net Cash from (invested) Operational Activities	**750,655**	**417,620**
Investment Activities Cash Flow		
PP&E and Intangible Acquisitions	(378,062)	(463,979)
PP&E Sale Payments	573	-
Restricted Investments	(23,772)	(6,761)
Acquisitions and capital contributions in investments, net	-	(20,700)
Cash from divestments	-	41,411
Net Cash from Investment Activities	**(401,261)**	**(450,029)**
Financing Activities Cash Flow		
Payments	(440,000)	-
Interest on Equity and Dividends Paid	(75)	(105)
Net Cash from Funding Activities	**(440,075)**	**(105)**
Cash and equivalents in the beggining of the period (with 4Bio)	**527,020**	**536,500**
Cash and equivalents net increase (with 4Bio)	(90,681)	(32,514)
Cash and equivalents in the end of the period (with 4Bio)	**436,339**	**503,986**